\-\ Texto\\:\\ \ \(0\)\
\-\ neurological\\ exam\\ was\\ significant\\ for\\ a\\ right\\ sided\\ central\\ facial\\ weakness\\ and\\ mild\\ right\\ sided\\ weakness\\ with\\ a\\ 4\\-5\\ beat\\ clonus\\.\\ some\\ difficulty\\ with\\ tandem\\ gait\\ and\\ decrease\\ in\\ right\\ arm\\ swing\\ was\\ observed\\ on\\ natural\\ gait\\.\ \(0\)\
\-\ the\\ patient\\ was\\ treated\\ initially\\ with\\ solumedrol\\,\\ and\\ then\\ switched\\ to\\ prednisone\\,\\ and\\ then\\ to\\ a\\ lower\\ dose\\ prednisone\\ and\\ imuran\\.\\ the\\ patient\\'s\\ disease\\ showed\\ good\\ response\\ to\\ the\\ steroids\\ and\\ immunosuppression\\.\ \(0\)\
\-\ serial\\ mri\\ was\\ done\\ to\\ follow\\ the\\ lesions\\,\\ which\\ also\\ showed\\ good\\ response\\ to\\ steroids\\.\ \(0\)\
\-\ mri\\ evaluation\\ was\\ significant\\ for\\:\ \(0\)\
\-\ \\â\\€\\¢\\ lesion\\ in\\ the\\ left\\ midbrain\\ with\\ t1\\ and\\ t2\\ signal\\ hyperintensity\\ that\\ enhances\\ with\\ contrast\\,\\ with\\ a\\ surrounding\\ area\\ of\\ t2\\ hyperintensity\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ lesions\\ in\\ the\\ pons\\,\\ thalamus\\,\\ and\\ medulla\\ found\\ in\\ the\\ white\\ matter\\ \\-\\ with\\ no\\ significant\\ mass\\ effect\\.\ \(1\)\
\-\ behcet\\ disease\\/syndrome\ \(0\)\
\-\ \\â\\€\\¢\\ adem\ \(0\)\
\-\ \\â\\€\\¢\\ inflammatory\\ disorders\\ including\\ behcet\\'s\ \(0\)\
\-\ \\â\\€\\¢\\ cerebritis\ \(1\)\
\-\ \\â\\€\\¢\\ rhombencephalitis\ \(1\)\
\-\ \\â\\€\\¢\\ cerebral\\ infarcts\ \(1\)\
\-\ a\\ 24\\ yo\\ right\\-hand\\ dominant\\ man\\ presented\\ with\\ a\\ 4\\ wk\\ course\\ of\\ insidious\\ onset\\ right\\ sided\\ weakness\\ including\\ facial\\ weakness\\ and\\ mild\\ dysarthria\\.\ \(0\)\
\-\ the\\ patient\\'s\\ initial\\ presentation\\ of\\ right\\ sided\\ weakness\\ can\\ be\\ explained\\ by\\ the\\ lesions\\ seen\\ on\\ mri\\.\\ however\\,\\ without\\ any\\ histological\\ specimens\\,\\ it\\ was\\ difficult\\ to\\ determine\\ the\\ exact\\ etiology\\ of\\ the\\ lesion\\.\\ \ \(0\)\
\-\ csf\\ analysis\\ pointed\\ in\\ the\\ direction\\ that\\ the\\ etiology\\ was\\ most\\ likely\\ to\\ be\\ inflammatory\\,\\ and\\ not\\ infectious\\,\\ and\\ the\\ trial\\ of\\ immunosuppression\\ proved\\ to\\ be\\ successful\\ clinically\\ as\\ well\\ as\\ radiographically\\.\\ \ \(0\)\
\-\ it\\ was\\ not\\ until\\ an\\ exacerbation\\ of\\ the\\ disease\\,\\ when\\ the\\ patient\\ presented\\ with\\ the\\ oral\\ and\\ genital\\ lesions\\,\\ that\\ the\\ clinical\\ diagnosis\\ of\\ behcet\\'s\\ disease\\ was\\ made\\.\ \(0\)\
\-\ the\\ diagnosis\\ led\\ to\\ a\\ further\\ advance\\ in\\ the\\ treatment\\ to\\ lower\\ the\\ steroid\\ dose\\ and\\ augment\\ with\\ imuran\\.\\ \ \(0\)\
\-\ radiographic\\ follow\\-up\\ of\\ the\\ lesions\\ proves\\ paramount\\ to\\ fine\\ tune\\ the\\ effective\\ dosages\\ of\\ the\\ medications\\,\\ thereby\\ preventing\\ the\\ patient\\ from\\ being\\ subjected\\ to\\ subtherapeutic\\ dosages\\ and\\ therefore\\ symptomatic\\.\ \(0\)\
\-\ this\\ case\\ is\\ a\\ good\\ example\\ of\\ a\\ combined\\ radiographic\\ and\\ clinical\\ diagnosis\\,\\ as\\ well\\ the\\ value\\ of\\ imaging\\ follow\\-up\\ \\-\\ playing\\ a\\ key\\ role\\ in\\ monitoring\\ the\\ course\\ of\\ treatment\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ imuran\\:\\ 0\\.043089502617541395\ \(0\)\
\-\ dosages\\:\\ 0\\.043089502617541395\ \(0\)\
\-\ weakness\\:\\ 0\\.0420903362470608\ \(0\)\
\-\ behcet\\:\\ 0\\.0372613207147928\ \(0\)\
\-\ immunosuppression\\:\\ 0\\.03644354522499302\ \(0\)\
\-\ sided\\:\\ 0\\.033522828786701805\ \(0\)\
\-\ lesions\\:\\ 0\\.03033899875787729\ \(0\)\
\-\ good\\:\\ 0\\.02909652353914034\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.029095757191435583\ \(0\)\
\-\ prednisone\\:\\ 0\\.026813359725585864\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.024958326577152183\ \(0\)\
\-\ dose\\:\\ 0\\.023722615395823946\ \(0\)\
\-\ was\\:\\ 0\\.023592832095286953\ \(0\)\
\-\ disease\\/syndrome\\:\\ 0\\.023383337994606096\ \(0\)\
\-\ augment\\:\\ 0\\.023383337994606096\ \(0\)\
\-\ tune\\:\\ 0\\.023383337994606096\ \(0\)\
\-\ response\\:\\ 0\\.022721055335879266\ \(0\)\
\-\ swing\\:\\ 0\\.021544751308770697\ \(0\)\
\-\ behcet\\'s\\:\\ 0\\.021544751308770697\ \(0\)\
\-\ rhombencephalitis\\:\\ 0\\.021544751308770697\ \(0\)\
\-\ right\\-hand\\:\\ 0\\.021544751308770697\ \(0\)\
\-\ subtherapeutic\\:\\ 0\\.021544751308770697\ \(0\)\
\-\ steroids\\:\\ 0\\.02132481633087404\ \(0\)\
\-\ gait\\:\\ 0\\.021110008047825042\ \(0\)\
\-\ solumedrol\\:\\ 0\\.0204692470432318\ \(0\)\
\-\ facial\\:\\ 0\\.019711681677147475\ \(0\)\
\-\ etiology\\:\\ 0\\.01918844240159508\ \(0\)\
\-\ pointed\\:\\ 0\\.019114271913879037\ \(0\)\
\-\ subjected\\:\\ 0\\.019114271913879037\ \(0\)\
\-\ proves\\:\\ 0\\.0186306603573964\ \(0\)\
\-\ paramount\\:\\ 0\\.0186306603573964\ \(0\)\
\-\ significant\\:\\ 0\\.018285255843932813\ \(0\)\
\-\ wk\\:\\ 0\\.01822177261249651\ \(0\)\
\-\ beat\\:\\ 0\\.0178675779370999\ \(0\)\
\-\ advance\\:\\ 0\\.0178675779370999\ \(0\)\
\-\ thereby\\:\\ 0\\.0175551560918575\ \(0\)\
\-\ tandem\\:\\ 0\\.01727568522804364\ \(0\)\
\-\ switched\\:\\ 0\\.01727568522804364\ \(0\)\
\-\ radiographic\\:\\ 0\\.017206177144767815\ \(0\)\
\-\ course\\:\\ 0\\.017106267604539212\ \(0\)\
\-\ genital\\:\\ 0\\.017022873080021556\ \(0\)\
\-\ including\\:\\ 0\\.016368268652482355\ \(0\)\
\-\ clonus\\:\\ 0\\.01620018096250474\ \(0\)\
\-\ then\\:\\ 0\\.016132450283406312\ \(0\)\
\-\ cerebritis\\:\\ 0\\.016028991251264498\ \(0\)\
\-\ specimens\\:\\ 0\\.015868183235836292\ \(0\)\
\-\ inflammatory\\:\\ 0\\.015720508987756093\ \(0\)\
\-\ dysarthria\\:\\ 0\\.015716569406022105\ \(0\)\
\-\ mri\\:\\ 0\\.015622884787118992\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01561447743326594\ \(0\)\
\-\ insidious\\:\\ 0\\.015573155025994849\ \(0\)\
\-\ preventing\\:\\ 0\\.01543709854220824\ \(0\)\
\-\ explained\\:\\ 0\\.015307681661122214\ \(0\)\
\-\ 4\\-5\\:\\ 0\\.01506637720964814\ \(0\)\
\-\ natural\\:\\ 0\\.01506637720964814\ \(0\)\
\-\ thalamus\\:\\ 0\\.01506637720964814\ \(0\)\
\-\ \\'s\\:\\ 0\\.014992413408756327\ \(0\)\
\-\ medulla\\:\\ 0\\.014953486985725602\ \(0\)\
\-\ showed\\:\\ 0\\.014863677813918815\ \(0\)\
\-\ proved\\:\\ 0\\.014845205833151982\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.014748206851149824\ \(0\)\
\-\ midbrain\\:\\ 0\\.014274618619313931\ \(0\)\
\-\ trial\\:\\ 0\\.014274618619313931\ \(0\)\
\-\ histological\\:\\ 0\\.014108782128647262\ \(0\)\
\-\ direction\\:\\ 0\\.014108782128647262\ \(0\)\
\-\ exacerbation\\:\\ 0\\.014108782128647262\ \(0\)\
\-\ exact\\:\\ 0\\.014029596550000892\ \(0\)\
\-\ clinical\\:\\ 0\\.01394859310379843\ \(0\)\
\-\ led\\:\\ 0\\.01373456834015945\ \(0\)\
\-\ adem\\:\\ 0\\.013665667845721092\ \(0\)\
\-\ to\\:\\ 0\\.013593679844339086\ \(0\)\
\-\ role\\:\\ 0\\.013406679862792932\ \(0\)\
\-\ key\\:\\ 0\\.01334569970835076\ \(0\)\
\-\ fine\\:\\ 0\\.013060207230386926\ \(0\)\
\-\ pons\\:\\ 0\\.012954092284461994\ \(0\)\
\-\ effective\\:\\ 0\\.012902585425424589\ \(0\)\
\-\ value\\:\\ 0\\.012852059709321954\ \(0\)\
\-\ t2\\:\\ 0\\.01283070964854298\ \(0\)\
\-\ radiographically\\:\\ 0\\.012523007590833945\ \(0\)\
\-\ combined\\:\\ 0\\.012523007590833945\ \(0\)\
\-\ monitoring\\:\\ 0\\.012523007590833945\ \(0\)\
\-\ example\\:\\ 0\\.012479163288576092\ \(0\)\
\-\ presented\\:\\ 0\\.012357334933805884\ \(0\)\
\-\ infarcts\\:\\ 0\\.012191009864165494\ \(0\)\
\-\ successful\\:\\ 0\\.012076494819430192\ \(0\)\
\-\ playing\\:\\ 0\\.012076494819430192\ \(0\)\
\-\ steroid\\:\\ 0\\.011966719710244902\ \(0\)\
\-\ right\\:\\ 0\\.011957980226928604\ \(0\)\
\-\ mild\\:\\ 0\\.011937684105735475\ \(0\)\
\-\ that\\:\\ 0\\.01174520473654236\ \(0\)\
\-\ dominant\\:\\ 0\\.011568093176957533\ \(0\)\
\-\ analysis\\:\\ 0\\.011537427865548844\ \(0\)\
\-\ determine\\:\\ 0\\.011477140727412091\ \(0\)\
\-\ patient\\:\\ 0\\.01136063568854626\ \(0\)\
\-\ serial\\:\\ 0\\.011304088945267791\ \(0\)\
\-\ disease\\:\\ 0\\.011114622343891545\ \(0\)\
\-\ observed\\:\\ 0\\.010867425869154915\ \(0\)\
\-\ disorders\\:\\ 0\\.010843847759294848\ \(0\)\
\-\ enhances\\:\\ 0\\.010706617853726707\ \(0\)\
\-\ therefore\\:\\ 0\\.010706617853726707\ \(0\)\
\-\ a\\:\\ 0\\.010519888642403217\ \(0\)\
\-\ be\\:\\ 0\\.010486127771967606\ \(0\)\
\-\ decrease\\:\\ 0\\.01037199905975615\ \(0\)\
\-\ as\\:\\ 0\\.01028576264637237\ \(0\)\
\-\ well\\:\\ 0\\.010255071368533958\ \(0\)\
\-\ lower\\:\\ 0\\.010195554744635875\ \(0\)\
\-\ it\\:\\ 0\\.01019017710627595\ \(0\)\
\-\ medications\\:\\ 0\\.010110270870082332\ \(0\)\
\-\ difficulty\\:\\ 0\\.010092528195942287\ \(0\)\
\-\ \\,\\:\\ 0\\.010052893679687064\ \(0\)\
\-\ until\\:\\ 0\\.009954703954746767\ \(0\)\
\-\ clinically\\:\\ 0\\.009937968757947656\ \(0\)\
\-\ difficult\\:\\ 0\\.009921338484702046\ \(0\)\
\-\ the\\:\\ 0\\.009901142405829965\ \(0\)\
\-\ neurological\\:\\ 0\\.009807757590317621\ \(0\)\
\-\ infectious\\:\\ 0\\.009744973123246254\ \(0\)\
\-\ \\-\\:\\ 0\\.009717392353890523\ \(0\)\
\-\ oral\\:\\ 0\\.009550617152141942\ \(0\)\
\-\ arm\\:\\ 0\\.009493571514951058\ \(0\)\
\-\ csf\\:\\ 0\\.009465502259432393\ \(0\)\
\-\ done\\:\\ 0\\.009396601764994036\ \(0\)\
\-\ lesion\\:\\ 0\\.009233714726792863\ \(0\)\
\-\ initially\\:\\ 0\\.009225412053753792\ \(0\)\
\-\ treatment\\:\\ 0\\.009175686788333618\ \(0\)\
\-\ made\\:\\ 0\\.009028839183319518\ \(0\)\
\-\ symptomatic\\:\\ 0\\.009005261073459447\ \(0\)\
\-\ matter\\:\\ 0\\.008924350054113522\ \(0\)\
\-\ 24\\:\\ 0\\.008812883237734614\ \(0\)\
\-\ effect\\:\\ 0\\.008025353456417094\ \(0\)\
\-\ being\\:\\ 0\\.007898641848277342\ \(0\)\
\-\ cerebral\\:\\ 0\\.007852643240753503\ \(0\)\
\-\ in\\:\\ 0\\.007824351753267332\ \(0\)\
\-\ presentation\\:\\ 0\\.007807428738703136\ \(0\)\
\-\ white\\:\\ 0\\.007517517805602169\ \(0\)\
\-\ initial\\:\\ 0\\.007510827966258111\ \(0\)\
\-\ central\\:\\ 0\\.007457908108381854\ \(0\)\
\-\ surrounding\\:\\ 0\\.007451366748978157\ \(0\)\
\-\ further\\:\\ 0\\.007208074646685035\ \(0\)\
\-\ follow\\:\\ 0\\.007202120615242531\ \(0\)\
\-\ t1\\:\\ 0\\.007184338292371999\ \(0\)\
\-\ area\\:\\ 0\\.0071666743876240505\ \(0\)\
\-\ and\\:\\ 0\\.00716216203178588\ \(0\)\
\-\ onset\\:\\ 0\\.00715496346399244\ \(0\)\
\-\ found\\:\\ 0\\.0071433040171143556\ \(0\)\
\-\ any\\:\\ 0\\.0071374934564251815\ \(0\)\
\-\ some\\:\\ 0\\.0068830988166227024\ \(0\)\
\-\ yo\\:\\ 0\\.006820561069768599\ \(0\)\
\-\ treated\\:\\ 0\\.006784750228339149\ \(0\)\
\-\ evaluation\\:\\ 0\\.006584187787339013\ \(0\)\
\-\ not\\:\\ 0\\.006550762184307349\ \(0\)\
\-\ when\\:\\ 0\\.0064915947947374155\ \(0\)\
\-\ likely\\:\\ 0\\.006393342084709964\ \(0\)\
\-\ 4\\:\\ 0\\.0063155753453025066\ \(0\)\
\-\ however\\:\\ 0\\.006311321102379497\ \(0\)\
\-\ signal\\:\\ 0\\.005976324483482172\ \(0\)\
\-\ man\\:\\ 0\\.0053605619180106074\ \(0\)\
\-\ without\\:\\ 0\\.005336904950552149\ \(0\)\
\-\ imaging\\:\\ 0\\.005310540648423349\ \(0\)\
\-\ most\\:\\ 0\\.005232984460817177\ \(0\)\
\-\ can\\:\\ 0\\.005141173348724323\ \(0\)\
\-\ contrast\\:\\ 0\\.005073675561824682\ \(0\)\
\-\ exam\\:\\ 0\\.004979400371218934\ \(0\)\
\-\ case\\:\\ 0\\.004958897699913185\ \(0\)\
\-\ multiple\\:\\ 0\\.004774021229387981\ \(0\)\
\-\ seen\\:\\ 0\\.004479118342354616\ \(0\)\
\-\ also\\:\\ 0\\.0044684869858624705\ \(0\)\
\-\ which\\:\\ 0\\.004231152751306495\ \(0\)\
\-\ for\\:\\ 0\\.0038679477381576397\ \(0\)\
\-\ on\\:\\ 0\\.0038402706226282656\ \(0\)\
\-\ by\\:\\ 0\\.0037741933773073597\ \(0\)\
\-\ of\\:\\ 0\\.0037083437919784115\ \(0\)\
\-\ from\\:\\ 0\\.003359245923485974\ \(0\)\
\-\ mass\\:\\ 0\\.003152416464051895\ \(0\)\
\-\ an\\:\\ 0\\.003134389560436949\ \(0\)\
\-\ with\\:\\ 0\\.0031035590474771816\ \(0\)\
\-\ \\:\\:\\ 0\\.002998076434988501\ \(0\)\
\-\ this\\:\\ 0\\.002549435579082581\ \(0\)\
\-\ left\\:\\ 0\\.0025360882474082616\ \(0\)\
\-\ no\\:\\ 0\\.0022823452273310397\ \(0\)\
\-\ is\\:\\ 0\\.0014914874758215533\ \(0\)\
\-\ \\.\\:\\ 0\\.0014124483858360586\ \(0\)\
